1. Home
  2. SCYX vs RDI Comparison

SCYX vs RDI Comparison

Compare SCYX & RDI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo SCYNEXIS Inc.

SCYX

SCYNEXIS Inc.

N/A

Current Price

$5.26

Market Cap

51.1M

Sector

Health Care

ML Signal

N/A

Logo Reading International Inc

RDI

Reading International Inc

HOLD

Current Price

$1.82

Market Cap

36.6M

ML Signal

HOLD

Company Overview

Basic Information
Metric
SCYX
RDI
Founded
1999
1937
Country
United States
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Movies/Entertainment
Sector
Health Care
Consumer Discretionary
Exchange
Nasdaq
Nasdaq
Market Cap
51.1M
36.6M
IPO Year
2014
1994

Fundamental Metrics

Financial Performance
Metric
SCYX
RDI
Price
$5.26
$1.82
Analyst Decision
Strong Buy
Analyst Count
1
0
Target Price
$3.00
N/A
AVG Volume (30 Days)
248.0K
73.3K
Earning Date
05-06-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
61.36
60.76
EPS
N/A
N/A
Revenue
$257,000.00
$202,988,000.00
Revenue This Year
N/A
$16.25
Revenue Next Year
$608.78
$4.04
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.57
$0.94
52 Week High
$5.62
$1.89

Technical Indicators

Market Signals
Indicator
SCYX
RDI
Relative Strength Index (RSI) 59.55 72.59
Support Level $4.65 $1.00
Resistance Level $5.56 N/A
Average True Range (ATR) 0.34 0.10
MACD -0.02 0.03
Stochastic Oscillator 55.75 84.75

Price Performance

Historical Comparison
SCYX
RDI

About SCYX SCYNEXIS Inc.

SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.

About RDI Reading International Inc

Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.

Share on Social Networks: